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Optogenetic induction of 
the schizophrenia-related 
endophenotype of ventral 
hippocampal hyperactivity  
causes rodent correlates of  
positive and cognitive symptoms
Amy R. Wolff1,2, Alexei M. Bygrave1, David J. Sanderson  1,3, Edward S. Boyden4, 
David M. Bannerman1, Dimitri M. Kullmann  2 & Dennis Kätzel1,2,5
Pathological over-activity of the CA1 subfield of the human anterior hippocampus has been identified 
as a potential predictive marker for transition from a prodromal state to overt schizophrenia. Psychosis, 
in turn, is associated with elevated activity in the anterior subiculum, the hippocampal output stage 
directly activated by CA1. Over-activity in these subfields may represent a useful endophenotype 
to guide translationally predictive preclinical models. To recreate this endophenotype and study 
its causal relation to deficits in the positive and cognitive symptom domains, we optogenetically 
activated excitatory neurons of the ventral hippocampus (vHPC; analogous to the human anterior 
hippocampus), targeting the ventral subiculum. Consistent with previous studies, we found that vHPC 
over-activity evokes hyperlocomotion, a rodent correlate of positive symptoms. vHPC activation also 
impaired performance on the spatial novelty preference (SNP) test of short-term memory, regardless 
of whether stimulation was applied during the encoding or retrieval stage of the task. Increasing 
dopamine transmission with amphetamine produced hyperlocomotion, but was not associated with 
SNP impairments. This suggests that short-term memory impairments resulting from hippocampal 
over-activity likely arise independently of a hyperdopaminergic state, a finding that is consistent with 
the pharmaco-resistance of cognitive symptoms in patients.
The pathophysiology of schizophrenia is complex, involving a wide range of brain areas and neurotransmitter 
systems. The hippocampus is implicated as having a central role, since it displays a number of alterations in schiz-
ophrenia, including reduced volume, changes in organisation and cytoarchitecture1–4, and altered expression of 
synaptic proteins2–5, and altered synaptic transmission6–9. Hippocampal dysfunction is also evident in imaging 
data from patients with schizophrenia, who show over-activation of the hippocampus, both at rest10–13, and dur-
ing tasks requiring minimal cognitive load14,15. Notably, such over-activity of anterior CA1 and subiculum has 
been correlated with the severity of positive, negative and, more recently, cognitive symptoms of schizophre-
nia10,11,16. It is not clear, however, if these symptoms are directly caused by over-activity of hippocampal output.
Altered hippocampal structure and function, including reduced hippocampal volume17 and anterior hip-
pocampal over-activity11 have also been reported in individuals at high-risk of developing schizophrenia. 
Evidence that hippocampal over-activity spreads from the CA1 region to the subiculum during the transition 
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from the prodromal to the psychotic state16 suggests that altered hippocampal function reflects a primary stage 
of impairment in schizophrenia, and that therapeutic intervention to regulate hippocampal activity could be 
effective in preventing disease progression16,18,19. Hippocampal over-activity may therefore represent a crucial 
biomarker20, and elucidating the mechanisms whereby this activity contributes to the different symptom domains 
may be a critical step in drug discovery.
The rodent hippocampal formation, including the ventral hippocampus (vHPC; analogous to the human 
anterior hippocampus), and particularly the ventral subiculum (vSUB), can modulate the activity of dopamin-
ergic neurons in the ventral tegmental area (VTA)21–25, and increase dopamine release in the nucleus accumbens 
(NAc)26–30. These changes to the midbrain dopaminergic system are also associated with hyperlocomotion31,32, 
a putative rodent correlate of positive symptoms in rodents33. It has therefore been proposed that hippocam-
pal over-activity contributes to the hyperdopaminergic state underlying the emergence of positive symptoms of 
schizophrenia34,35. In support of this hypothesis, activation of the vHPC (with electrical or chemical stimulation) 
has previously been shown to produce rodent correlates of positive symptoms in translational paradigms such 
as pre-pulse inhibition and latent inhibition36,37. It has also been shown, in a developmental rat model of schiz-
ophrenia (methylazoxymethanol acetate), that the altered activity of VTA dopaminergic neurons and increased 
locomotor responses to amphetamine can be normalized by pharmacological inhibition of the vHPC38.
Genetically and spatially targeted manipulation of neural circuits using optogenetics provides a novel class of 
rodent models of psychiatric diseases, which are more specific and mechanistically defined than previous phar-
macological or transgenic models39. With this approach, physiological endophenotypes (i.e. abnormal circuit 
activity) observed in patients can be precisely recreated in rodents, and can be used to test whether such abnormal 
physiological activity plays a causal role in specific symptoms. If so, they represent a biomarker in preclinical drug 
screening39 and clinical monitoring of therapeutic efficacy. Furthermore, this approach allows temporal control 
not afforded by previous techniques. For example, in contrast to chemical stimulation, optogenetics can model 
over-activation during specific epochs of behavioural tasks. Additionally, unlike electrical stimulation, manipu-
lations can be targeted to the soma of specific cell types, leaving fibres of passage unaffected. Using such precise 
tools of control, the targeted re-creation of endophenotypes of abnormal neurophysiological activity observed 
in patients might be a promising novel route to derive optogenetic rodent models with relevance to psychiatric 
disorders40. This approach has, however, not yet been widely adopted in the context of schizophrenia41–44.
To explore the mechanistic link between increased hippocampal output, dopaminergic regulation, and cogni-
tive impairment, we aimed to optogenetically re-create the endophenotype of anterior hippocampal over-activity 
observed in patients. The effects of electrical stimulation and pharmacological activation of the hippocampus in 
rodents are thought to be mediated by increased activity of excitatory projection neurons at the vHPC output 
stage – the vSUB23–25,35. Therefore, we aimed to selectively activate excitatory neurons of the vSUB, and assess the 
effects of this manipulation on novelty-induced hyperlocomotion and hippocampus-dependent short-term mem-
ory performance (assessed with the Y-maze spatial novelty preference task45). While the mechanisms whereby 
increased hippocampal activity leads to hyperlocomotion in rodents have been extensively studied29,46,47, the link 
between hippocampal over-activity and cognitive impairment are less clear48.
Results
Histology. To allow activation of excitatory vSUB output neurons, we injected the optogenetic activator 
Chronos bilaterally into the vHPC of CamKIIα-Cre mice, and implanted optic fibres for light delivery. Optic 
fibre tracts were not visible in their entirety in the sliced tissue; therefore the precise location of the tips of the 
optic fibres could not be determined in every experimental animal. Additional animals in which optic fibres were 
coated in fluorescent DiI and implanted at the same coordinates demonstrated that the placements effectively tar-
geted light towards the vSUB (see Fig. 1a). Furthermore, in cases where partial tracts were visible in experimental 
animals, the AP coordinates and ML locations were entirely consistent with these data.
All Chronos-transfected animals meeting the optogenetic stimulation calibration criteria (see Methods; 
n = 18) had expression in the targeted vSUB area in the stimulated hemisphere (Fig. 1a; left panel, Fig. 1b). 
Many animals also had some strong expression in parts of the adjacent ventral CA1 subfield (16/18) and/or weak 
expression in the ventral DG (14/18) and CA3 (9/18). Viral expression outside the vHPC was seen in only 4/20 
animals, where weak expression was also evident in parts of the amygdalopiriform transition area, posteromedial 
cortical amygdaloid area, and the posteromedial amygdalohippocampal area, which are adjacent to the vSUB. 
Given the placement of the optical fibre just above vSUB (see Fig. 1a; right panel), the low light powers used, and 
weak offsite expression, it is unlikely that the light effectively stimulated transfected subfields outside of the vSUB/
vCA1. Nevertheless, we refer to our manipulation as vHPC (not vSUB) stimulation, to acknowledge the potential 
contribution of induced overactivity in adjacent hippocampal subfields to the observed behavioural effects.
Behaviour. Calibration of optical stimulation intensity. We first calibrated stimulation levels in the Chronos 
group to determine the level of stimulation just sufficient to produce hyperlocomotion via either one of the bilat-
erally implanted optic fibres (i.e. hemispheres, see Methods). The individually determined power values (mean 
power = 3.4 mW, range: 2–5 mW) and the unilateral stimulation configuration were kept for the remainder of the 
test battery to minimize the risk of optogenetic over-stimulation or the induction of seizures. Animals exhibiting 
seizures (n = 4), or failing to show hyper-locomotion with optical stimulation at 5 mW in either hemisphere 
(n = 7) during calibration were excluded from all subsequent tests. Our observations indicated that susceptibility 
to seizures was likely due to strong off-target expression in the dentate gyrus and/or CA3 seen in some mice.
Optogenetic stimulation of the vHPC induces hyperlocomotion. After calibration, we confirmed that the same 
stimulation intensity elicited hyperlocomotion in a novel open field. Locomotor activity (distance travelled) 
was measured for 30 minutes and scored in 3-min bins, with 3 minutes of stimulation starting at minute 15. We 
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Figure 1. Optogenetic activation of the vHPC induces hyperlocomotion. (a) Selective transfection of the vHPC 
(vSUB & vCA1) is indicated by GFP-fluorescence (left) derived from the transfected Chronos-GFP expression 
cassette. Blue background stain with DAPI. Note that the dorsal fluorescence is autofluorescence from damage 
to the tissue, rather than Chronos-GFP expression. Photomicrograph of the location of vertically implanted 
optic fibre coated in DiI (red) 100–200 µm above the pyramidal cell layer of the vHPC (right; DiI was not 
applied in experimental animals). (b) High-resolution image to illustrate the membrane-bound expression of 
Chronos-GFP (green) in the somata (vSUB PC-s) and dendrites (vSUB PC-d) of pyramidal cells of the vSUB. 
Scale bar = 100 µm; blue, DAPI stain; the ventral pole is left, the dorsal pole right. This image is from a separate 
animal not used for behavioural testing. (c) Optogenetic induction of hyperlocomotion during stimulation 
(block starting at minute 15; green shaded area) in the pre-screened cohort in a novel open field. Inset (top 
right) shows locomotion calculated for each min of the 3 min stimulation as a % of baseline (min 15–18). 
(d) Data of (c) expressed as distance moved during the stimulation-phase (during-stim; green shading), and 
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calculated the distance travelled during the stimulation block as a percentage of the average distance travelled 
during the baseline period (previous 3 bins; 3 min each; from min 6) to assess hyperlocomotion. Again, we found 
that the change in locomotion during optogenetic stimulation in Chronos-transfected animals was significantly 
higher than in GFP controls (Fig. 1c,d; stimulation as % of baseline: D(28) = 1.59, p = 0.01; Kolmogorov-Smirnov 
Z Test; n = 14 Chronos, 16 Controls). The relative increase in locomotion during the stimulation period was sig-
nificantly greater than baseline (100%) in Chronos animals (p = 0.004; One-Sample Wilcoxon Sign Rank Test), 
but not in GFP-transfected controls (p = 0.92; One-Sample Wilcoxon Sign Rank Test). The effects of stimulation 
on locomotion showed a non-significant trend to increase over each minute of the 3 min stimulation in Chronos 
animals (see Fig. 1c, inset; χ2(2) = 2.71, p = 0.26; Related-Samples Friedman’s). Additionally, we found that 
locomotion relative to baseline was significantly higher in the Chronos group than in controls during the 3 min 
block after stimulation (Fig. 1d; minutes 18–21; first post-stim block as % of baseline: D(28) = 1.39, p = 0.04, 
Kolmogorov-Smirnov Z Test). As unilateral manipulations may produce turning behaviour49, we also assessed 
rotations during the optogenetic stimulation. Chronos animals turned significantly more than GFP-transfected 
controls during the stimulation (3 min; t (28) = 2.32, p = 0.03; number of turns: Chronos = 8.4 ± 1.1, 
GFP = 5.6 ± 0.6; Mean ± SEM). However, there were no group differences in the percentage of contralateral turns 
during stimulation (% controlateral rotations; D(28) = 0.66, p = 0.78, Kolmogorov-Smirnov Z Test), and there 
was no evidence of bias for turning towards the contralateral side (% contralateral turns: Chronos = 49.7 ± 6.8%, 
GFP = 56.3 ± 6.6%; Mean ± SEM). It is likely that increased rotations in the Chronos group reflect the general 
increase in locomotor activity resulting from vHPC stimulation, rather than an induction of circling.
Role of dopamine D2-receptors in mediating hyperlocomotion induced by optogenetic stimulation of vHPC. 
According to a prominent circuit model of schizophrenia21 the primary, albeit indirect, downstream effect of an 
over-active vHPC is increased burst firing of dopaminergic neurons in the VTA, which innervate the NAc. This 
leads to the prediction that the transient increase in locomotion caused by optogenetic stimulation of the vHPC 
(Fig. 1c,d) should be eliminated by D2R-antagonism. To test this hypothesis, we injected raclopride, a selective 
and potent D2/3-antagonist (Rac; 1 mg/kg), or vehicle (Veh) one hour before testing the effect of optogenetic 
vSUB stimulation (Fig. 1e,f). We observed a strong suppression of baseline locomotion by raclopride, which con-
founds further analysis of relative locomotor activity during stimulation normalized to baseline locomotion (see 
Fig. 1f for relative values calculated as for Experiment 1).
Instead, we assessed the absolute values of locomotion using a 3-way ANOVA with repeated measures of 
phase (baseline vs. stimulation) and drug (vehicle vs. raclopride), and a between-subject factor of group (Chronos 
vs. GFP). Relative to vehicle, raclopride strongly suppressed locomotion in both groups throughout testing, as 
evidenced by a main effect of drug and the lack of significant drug × group and drug × phase interactions (see 
Fig. 1e; drug: F(1, 26) = 51.58, p < 0.001; drug × group: F(1, 26) = 0.90, p = 0.35; drug × phase: F(1, 26) = 0.24, 
p = 0.63). There was no overall effect of group (F(1, 26) = 1.08, p = 0.31), but a significant main effect of phase 
(F(1, 26) = 9.86, p = 0.004), indicating a locomotor-increasing effect of the optical stimulation irrespective of drug 
and group (see Fig. 1e–h). Furthermore, the group × phase interaction (F(1, 26) = 10.46, p = 0.003), and group × 
phase × drug interactions were both significant (F(1, 26) = 8.63, p = 0.007).
To further explore these interactions, separate 2-way repeated-measures ANOVAs analysing the effect of drug 
and test phase were conducted within each group (Fig. 1g,h). In the Chronos group, there was a significant effect 
of phase and drug (phase: F(1, 11) = 8.03, p = 0.02; drug: F(1, 11) = 41.16, p < 0.001), but no significant drug × 
phase interaction (F(1, 11) = 1.61, p = 0.23), implying that raclopride reduced baseline locomotion throughout, 
but was ineffective against the laser-induced increase of locomotion (Fig. 1h). In contrast, in the GFP controls, 
there was a significant drug × phase interaction (F(1, 15) = 12.73, p = 0.003), but, in turn, no main effect of 
phase (F(1, 15) = 0.05, p = 0.83), while a significant effect of drug (F(1, 15) = 18.60, p = 0.001) remained. This 
implies (see Fig. 1g) that, although the stimulation did not increase locomotion in the GFP-group in general, 
there was a stimulation-induced increase exclusively in the raclopride condition. This may be due to reinvigor-
ation of exploration by the presentation of a prominent visual cue (the laser light) on a low background level of 
locomotion. An additional 2-way group × phase ANOVA within the raclopride condition revealed a significant 
effect of phase (F(1, 26) = 7.98, p = 0.009), but no main effect of group (F(1, 26) = 0.26, p = 0.62), or group × 
phase interaction (F(1, 26) = 1.87, p = 0.18). This indicates that the stimulation-induced increase in locomotion in 
the raclopride-treated Chronos group was not significantly greater than the stimulation-related increase seen in 
raclopride-treated GFP controls (Fig. 1i). Together, these results indicate that raclopride failed to prevent the spe-
cific increase of locomotion during the stimulation period, despite effective suppression of baseline locomotion. 
the first post-stimulation block (post-stim) as a percentage of the average distance moved during baseline 
(3 blocks immediately before stimulation; grey shading). (e,f) Same experiment as in (c), with injection of 
vehicle (Veh; grey) or the D2R antagonist raclopride (Rac; 1 mg/kg; blue) 1 h before the start of the experiment. 
Optogenetic stimulation in minutes 15–18 (green shading), with baseline period shown in grey shading. (f) 
Locomotion during optogenetic stimulation of the vHPC (stimulation as % of baseline) following vehicle (grey) 
or Raclopride (blue) injection. (g–i) Absolute changes in locomotion from baseline to stimulation phase are 
shown separately for the GFP controls (g) and Chronos animals (h), and for both groups following Raclopride 
injection (i). Indication of significant effects or interactions are omitted from (c, e, f, and g–i) for clarity, see 
main text for analysis. Data are shown as mean ± SEM; *p < 0.05, **p < 0.01, Kolmogorov-Smirnov Z Test. 
Abbreviations, DG: dentate gyrus; DG MoL, molecular layer of the DG; CA1: cornu ammonis area 1; vSUB: 
ventral subiculum; APir: amygdalopiriform transition area; VIEnt: ventral intermediate entorhinal cortex; 
AHiPM: amygdalohippocampal area, posteromedial part; PMCo: posteromedial cortical amygdaloid area.
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However, as there was no significant group difference under raclopride, it is possible that this raclopride-resistant 
locomotor increase reflects non-specific arousal caused by the laser pulses, rather than a direct optogenetic effect.
Optogenetic stimulation of vHPC alters spatial novelty preference. We next used a task assessing hippocampus- 
dependent short-term memory45 to investigate the effect of vHPC over-activity on cognitive function. We tested 
spatial novelty preference in the Y-maze following optogenetic activation of the vHPC during different phases of 
the task (see Fig. 2a,b). We stimulated the vHPC either during the sample phase (5 min), the ITI (1 min), the test 
phase (2 min), or throughout both the ITI and the subsequent test phase (3 min). Novelty-preference was calcu-
lated as the ratio of time spent in the novel arm divided by time spent in both choice arms combined (excluding 
the start arm). Locomotion was assessed by distance travelled (m) and was converted to speed (m/min) to nor-
malize data relative to the duration of each phase of testing.
We verified that Chronos animals (n = 10) showed hyperlocomotion relative to GFP controls (n = 16) during 
the phase of the test in which stimulation was applied (Fig. 2c; Sample: t(24) = 4.54, p < 0.001; Test: D(24) = 1.43, 
p = 0.034; ITI + Test: D(24) = 1.36, p = 0.048; activity levels were not tracked in the holding cage and therefore 
locomotor data for the ITI-only condition are not available). This hyperactivity confirmed that optogenetic stim-
ulation was effective.
Optogenetic vHPC stimulation did not affect the time spent in both goal arms combined during the test phase 
(NOV + FAM; Sample: t(24) = −0.43, p = 0.67; ITI: t(24) = 0.52, p = 0.61; Test: D(24) 0.78, p = 0.59; ITI + Test: 
t(24) = 0.679, p = 0.50). However, vHPC stimulation significantly impaired spatial novelty preference when con-
ducting an ANOVA with stimulation condition (ITI + Test, ITI, Test, Sample) as a repeated measure in those 
animals where data was available for all stimulation conditions (Fig. 2d; n = 10 Chronos, 16 GFP). There was a 
significant main effect of group (GFP vs Chronos; F(1, 24) = 6.32, p = 0.019), but no significant effect of stimu-
lation condition (F(3, 72) = 0.31, p = 0.819), and no interaction (F(3, 72) = 1.36, p = 0.262), indicating that stim-
ulation of the vHPC during any stage of testing in Chronos animals impaired task performance to some degree 
(Fig. 2b,d,e). Importantly, SNP impairments were not due to insufficient exploration during the sample phase, as 
the time spent in the open goal arm during the sample phase did not differ between groups for any of the stim-
ulation paradigms (Sample: t(24) = −1.38, p = 0.18; ITI + Test: t(24) = 1.02, p = 0.32; ITI: D(24) = 0.37, p = 1.0; 
Test: t(24) = −0.2, p = 0.85).
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Figure 2. Optogenetic impairment of spatial novelty preference (SNP). (a) Illustration of the Y-maze test protocol 
used to assess SNP. In all cases animals were familiarized to a novel cage and the tether before introduction into 
the Y-maze (acclimation). Green lines above indicate the phase of optogenetic stimulation for the 4 different 
stimulation phases used: (1) sample phase (Sample) (2) Intra-trial interval (ITI) (3) test phase (Test) and (4) ITI 
and test phase (ITI + Test). (b) Example path lengths from individual GFP (left) and Chronos animals (right) 
are shown for exploration during the test phase following stimulation in the sample phase (top) or the ITI + Test 
phase (bottom). The novel arm is indicated by the arrow. (c) Optogenetically-induced hyperlocomotion was 
observed during stimulation for each stimulation phase during which locomotion was recorded; locomotion was 
not tracked in the holding cage, and is therefore not shown for the ITI only stimulation condition, and data for 
ITI + Test stimulation are shown for the test phase only. (d,e) Preference ratios for the novel arm calculated as 
the ratio of the time spent in the novel goal arm to the time spent in both goal arms. Data are presented averaged 
across all 4 stimulation phases (reflecting the main effect of group from the ANOVA; d) or individually for each 
stimulation protocol (e). The dashed lines (d–e) indicate chance level (0.5), i.e. equal preference for both goal arms. 
Data are shown as mean ± SEM; *p < 0.05, ***p < 0.001; t-Test or Kolmogorov-Smirnov Z-Test.
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Optogenetic stimulation of the vHPC does not alter anxiety or induce place preference. Optogenetic induction of 
vHPC over-activity impaired SNP, implying an impairment of short-term memory. However, novelty-preference 
could also be altered due to emotional or motivational changes, rather than cognitive deficits. Firstly, activation 
of the vHPC could reduce the preference for novel places by altering the balance between exploratory drive and 
unconditioned anxiety23, since manipulations of the ventral hippocampus may affect anxiety50–53. If vHPC acti-
vation increases anxiety, this could compete with the drive towards exploration of the novel arm during the nov-
elty preference test. A second potential confound is that the optogenetic stimulation itself, through downstream 
effects on the dopaminergic system54, might be perceived as rewarding, and therefore induce a place preference 
(PP) for the location in which the optogenetic stimulation occurred (i.e. the familiar arm when stimulated during 
the sample trial). This preference would then conflict with the drive to explore the novel arm for the sample-only 
stimulation condition.
We assessed both these potential explanations. First, we used the elevated plus- maze to measure exploration/
anxiety balance and stimulated the vHPC starting 30 s before placement on the maze, and continuing for the first 
half (2.5 min) of maze exploration (see Fig. 3a). Again, we successfully induced hyperlocomotion compared to 
GFP-controls during the stimulation period (Fig. 3b; t(25) = 3.45, p = 0.002; n = 13 Chronos, 14 GFP). However, 
the preference for the time spent in the open arms during stimulation was not altered in the Chronos group com-
pared to controls (Fig. 3c; D(25) = 0.49, p = 0.973; Kolmogorov-Smirnov Z Test).
Second, to test for the possibility of an optogenetic induction of a place preference using the same expo-
sure (5 min) and ITI times (1 min) as the Y-Maze task, we adapted this paradigm to resemble a conditioned 
stim stim
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Figure 3. Optogenetic activation of the vHPC does not alter anxiety or place preference. (a) Experimental 
paradigm used to assess anxiety following optogenetic stimulation (green), with bold lines indicating walled 
arms of the elevated plus-maze (EPM) apparatus. Locomotion (b) and preference for the open arm (c) on the 
EPM. Data are presented for the first half (2.5 min) of the test on the EPM (when optogenetic stimulation was 
applied). Preference for the open arms was measured as the percentage of time spent in the open arms relative 
to time spent in all open and closed arms. (d) Experimental paradigm for testing short-term place preference 
(PP) in the modified Y-Maze apparatus, delivery of optogenetic stimulation is shown in green. (e) Locomotor 
activity in the individual phases of the test: first sample phase, with no stimulation (No Stim); second sample 
phase, with stimulation (Stim); and test phase (Test). (f) Preference ratio measured as time spent in the goal arm 
of the Y-maze in which optogenetic stimulation was delivered relative to time in both goal arms. Dashed line 
indicates chance performance (i.e. equal preference for both goal arms). (g) Experimental paradigm for testing 
long-term place preference in a modified 3-chamber apparatus. (h) Locomotion during different phases of test. 
(i) Preference ratios for time spent in the chamber of the apparatus in which stimulation was applied during the 
test phase conducted 24 h later. Dashed line indicates chance performance (i.e. equal preference for both goal 
arms). *p < 0.05, **p < 0.01; t-Test or Kolmogorov-Smirnov Z-Test. Data are shown as mean ± SEM.
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place preference paradigm (see Fig. 3d). In contrast to the SNP test, mice sampled both goal arms separately 
before the test phase, while only exploration of the second goal arm was accompanied by optogenetic stimulation 
of the vHPC. Again, we could induce hyperlocomotion in Chronos animals selectively during the optogenetic 
stimulation phase compared to controls (Fig. 3e; Non-Stim: t(27) = −0.10, p = 0.92: n = 15 Chronos, 14 GFP; 
Stim: t(25) = 2.08, p = 0.048: n = 13 Chronos, 14 GFP; Test: t(27) = −0.55, p = 0.59: n = 15 Chronos, 14 GFP). 
Nevertheless, there was no evidence of a subsequent preference for the arm that was paired with stimulation in 
Chronos animals (preference vs 0.5; t(14) = −1.03, p = 0.32), and no significant difference between the groups 
(Fig. 3f; t (1, 27) = −0.52, p = 0.606; n = 15 Chronos, 14 GFP).
Note, however, that in this paradigm, it was not possible to counterbalance the order of stimulation vs no 
stimulation due to potential carry-over effects of optogenetic stimulation. (i.e. Stimulation during the first sample 
would also potentially effect the second sample), as hyperlocomotion persisted for at least 3 min after stimulation; 
(see Fig. 1b,c). Counter-balancing the order of stimulation would have additionally separated the stimulation 
from the test phase by delays longer than those used in the Y-maze task.
Nevertheless, it is therefore possible that the lack of any effect results from competition between place 
preference (preferred exploration of the stimulated arm), and recency, which would drive preference for the 
non-stimulated arm (i.e. the less recently experienced arm). To address this issue, we conducted a long-term place 
preference task during which the sample phases were separated by 2 hours, allowing for counterbalancing of the 
stimulation/no stimulation order (see Fig. 3g). Note that Chronos animals only showed a trend towards hyper-
locomotion during the stimulation in this case (Fig. 3h; D(28) = 1.27, p = 0.08; Kolmogorov-Smirnov Z Test). 
However, in the test phase (24 h later), there was still no evidence of a preference for the stimulated chamber of the 
apparatus in Chronos animals (preference ratio vs 0.5; t(14) = 0.420, p = 0.68), and no significant group difference 
(Fig. 3i; D(28) = 0.85, p = 0.459; Kolmogorov-Smirnov Z Test, n = 14 Chronos, 16 GFP). Together, these results 
indicate that optogenetic stimulation does not impair novelty preference by increasing anxiety or the rewarding 
value associated with the stimulated arm.
Increased dopamine transmission does not impair spatial novelty preference. Given that optogenetic vHPC stim-
ulation impaired spatial short-term memory during the SNP task, and that the hyperactivity induced by vHPC 
stimulation is associated with increased dopaminergic transmission26,27,31, we asked whether increased dopamine 
transmission alone is sufficient to alter SNP. We assessed SNP in control mice injected with the pro-dopaminergic 
drug amphetamine (Fig. 4a; Amph), at a dose known to produce robust locomotor hyperactivity55. As expected, 
amphetamine (2.5 mg/kg) led to strong hyperlocomotion relative to vehicle-injected mice (Veh) during both the 
sample and test phases of the task (Fig. 4b; sample: t (21) = −5.63, p < 0.001; test: t (13.79) = −8.62, p < 0.001). 
Amphetamine administration did not alter the time spent exploring the goal arm during the sample phase 
(t (21) = −1.43, p = 0.17), or the time spent in both goal arms combined during the test phase (Novel + Familiar; 
t (21) = 0.37, p = 0.71). Importantly, amphetamine-treated mice showed a similar novel arm preference to 
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Figure 4. Increased dopamine is not sufficient to induce impairments in spatial novelty preference. (a) 
Experimental paradigm for assessing the effects of the dopamine agonist amphetamine (2.5 mg/kg; Amph) 
administered 30 min before testing on (b) hyperlocomotion and (c) novelty preference. (b) Amphetamine 
administration in wild type mice produced hyperlocomotion relative to vehicle-treated controls (Veh) during 
both the sample and test phases of the SNP task. (c) Novelty preference ratios for the time spent in the novel arm 
relative to the time spent in both goal arms combined did not differ between Amph and Veh injected mice, and 
performance in both groups was above chance level (Dashed line = 0.5; i.e. equal preference for both goal arms). 
***p < 0.001, t-Test.
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vehicle-injected controls (Fig. 4c; t(15.68) = 0.06, p = 0.95). Furthermore, preference ratios for both groups were 
significantly above chance (Veh: t(10) = 4.51, p = 0.001; Amph: t(11) = 8.17, p < 0.001), i.e. both groups spent sig-
nificantly more time exploring the novel compared to the familiar arm, suggesting that they had intact short-term 
memory for the arm visited in the sample phase.
Discussion
Here we aimed to model schizophrenia-related over-activity of ventral hippocampal (vHPC) output by using 
optogenetics to selectively activate excitatory projection neurons of the vHPC, specifically targeting the ventral 
subiculum (vSUB). In addition to high spatial, temporal and genetic resolution, allowing more controlled mod-
elling of vHPC hyperactivity than earlier approaches (chemical/electrical stimulation), the calibration of stimu-
lation power for each animal allows for a similar level of activation across animals. While the applied stimulation 
frequency of 20 Hz probably does not exactly recapitulate the hippocampal hyperactivity seen in patients and may 
not represent endogenously produced spike activity, it is known to effectively increase dopamine transmission in 
the nucleus accumbens (NAc) and locomotor activity in rodents when used for electrical vHPC stimulation28–30. 
It therefore effectively models the hypothesized hyperdopaminergic downstream effects of such changes in the 
anterior HPC in patients. We found that optogenetic induction of vHPC over-activity causes robust hyperlocomo-
tion and a hippocampus-dependent memory deficit; putative rodent correlates of positive and cognitive symp-
toms of schizophrenia, respectively. We also show that these features are likely dissociable, as only the induction 
of hyperlocomotion is mimicked by elevating dopaminergic signalling.
The locomotion-promoting effect of the previously described pharmacological or electrical stimulation of 
the vHPC22,29,47 has been proposed to result from increased firing of VTA dopamine neurons, and subsequent 
increases in dopamine release in the NAc21,26,38. D2 receptors in the NAc are known to be necessary for mediating 
spontaneous locomotion56. To establish whether such a D2-dependent mechanism also underlies the hyperloco-
motion produced by optogenetic stimulation of the vHPC, we tested the effect of the D2-antagonist raclopride 
on optogenetically-induced hyperlocomotion. Raclopride did not significantly decrease the effect of optogenetic 
stimulation on relative levels of locomotion, akin to hyperlocomotion produced by electrical vHPC stimulation in 
rats29. However, we also observed an increase in locomotion during stimulation in the GFP control group treated 
with raclopride, which might have resulted from the salient visual stimulus of the laser light re-invigorating explo-
ration in these partially sedated animals. Consequently, the group comparison within the raclopride condition 
revealed statistically similar stimulation-induced increases in locomotion in both groups, raising the possibility 
that the raclopride-resistant increase in the Chronos group was induced non-specifically by the laser light rather 
than optogenetically.
We also found that optogenetic stimulation of the vHPC impaired performance on a test of 
hippocampus-dependent short-term memory, suggesting that hippocampal over-activity in rodents may lead to 
phenotypes that are potentially relevant to the cognitive symptoms of schizophrenia. Furthermore, these differ-
ences in SNP are not explained by alterations in anxiety or potential rewarding effects of vHPC optogenetic stim-
ulation. A previous study found that silencing hippocampal projections to the medial prefrontal cortex (mPFC) 
specifically during the encoding, but not the retrieval phase of a spatial short-term memory task reduced perfor-
mance57. In contrast, in our study, the lack of an interaction between group and stimulation phase indicated that 
activation of the vHPC is detrimental to spatial short-term memory regardless of whether stimulation occurs 
during the encoding or retrieval phases of the task. This could arise from disruptions of state-dependent memory 
processes, whereby performance is impaired as a result of changes in behavioural state between encoding and 
retrieval. However, given that the effects of optogenetic stimulation (and presumably the associated behavioural 
state) were found to outlast the stimulation period on a timescale of several minutes (see Fig. 1b,c), the impair-
ment in animals stimulated during the sample phase only would argue against this explanation.
An important question relates to the mechanism underlying the cognitive impairment. In particular, we 
addressed whether the short-term memory impairment induced by over-activation of the vHPC could result 
from the well-described induction of a hyperdopaminergic state. It was not possible to evaluate the role of dopa-
mine signalling in this study using the same pharmacological approach that was used previously in the hyperlo-
comotion test, as raclopride was found to decrease baseline locomotion in all animals, and exploration is critical 
for the novelty preference task. Therefore, we did the reverse experiment, and tested whether pharmacologically 
increasing dopamine signalling alone was sufficient to induce impairments in the Y-maze SNP task. We found that 
wild-type mice injected with a dose of amphetamine sufficient to produce robust hyperlocomotion did not show 
short-term memory impairments. This suggests that the cognitive impairment induced by vHPC hyperactivity 
is likely independent of increased dopamine transmission. Admittedly, this conclusion is indirect, as it is unclear 
if systemic amphetamine at the given dose reproduces the effect of optogenetic vHPC stimulation on dopamine 
neurotransmission in terms of magnitude, time course, and regional specificity. Nevertheless, the present results 
do show that an impairment in SNP cannot simply arise from an elevation of dopamine signalling, or locomotor 
hyperactivity alone.
This model of optogenetic over-activation provides a valuable tool to study which schizophrenia-related defi-
cits and symptom domains may be caused by an overactive hippocampus, and to what extent elevated dopa-
mine signalling is involved, or indeed, other downstream brain structures. Manipulations of the dorsal HPC, the 
nucleus reuniens of the thalamus, and the mPFC have been shown to alter performance on working memory 
tasks44,58–60, and the hyperactivity of the vHPC might influence short-term memory through direct projections via 
these regions, independent of polysynaptic loops through the dopamine system61,62. This would support our claim 
that the dopamine-related phenotypes and the memory impairments induced by vHPC stimulation are dissocia-
ble. For example, in a direct comparison of the effects of pharmacological or electrical stimulation of the dorsal 
vs. the ventral hippocampus, only the latter resulted in increased activity of the mesolimbic dopamine system and 
www.nature.com/scientificreports/
9SCIENTIfIC RepORTS |  (2018) 8:12871  | DOI:10.1038/s41598-018-31163-5
produced phenotypes linked to the positive symptom domain37,63. This anatomical separation of downstream 
effects of vHPC hyperactivity is consistent with the observation that antipsychotics, which act primarily on the 
dopamine system, are largely ineffective against cognitive symptoms of schizophrenia.
Materials and Methods
Surgery. To allow activation of excitatory vSUB output neurons, we exploited the fast kinetics and high appar-
ent light sensitivity of the optogenetic activator Chronos (ChR90), with GFP as a reporter protein64. Twenty-
nine adult male CamKIIα-Cre mice on a C57BL/6 background (B6.Cg-Tg(Camk2a-cre)T29-1Stl/J, Jackson 
Laboratories strain # 005359, MA, USA) were transfected bilaterally with AAV8-EF1α-FLEX-Chronos-GFP 
(5.1 * 1012 IU/ml) and 16 male littermates with AAV5-hSyn-FLEX-GFP (3.4 * 1012 IU/ml), targeting the vSUB 
using an angle of 25 (right hemisphere) or 23 (left hemisphere) degrees towards the midline at AP-3.3 mm, ML 
+/− 4.5 mm, and 3.3 mm distance from pia (Fig. 1a, left). Viral vector suspensions (80 nl) were infused (100 nl/
min) through Hamilton syringes with bevelled needles (34 G), with the bevel facing laterally. The needle was 
left for 10 min before withdrawal to reduce backflow. Viral vectors were obtained from the University of North 
Carolina viral vector core. Optic fibres (1.25 mm ferrule diameter; Thorlabs, UK) cut to a length of 5.5–6 mm, 
were implanted bilaterally at AP −3.3 mm, ML +/− 2.8 mm from bregma and 3.9 mm below pia and fixed in 
place with dental cement and jewellers screws (Fig. 1a, right; Kemdent, UK). All experiments were in accordance 
to the Animal (Scientific Procedures) Act 1986, UK, and were approved by the Local Ethical Review Committee 
at the University of Oxford and the Home Office of the United Kingdom.
Behavioural testing. Optogenetic stimulation. Green-light pulses were produced by a TTL-modulated 
DPSS laser (532 nm, CNI Lasers, China) using a computer-controlled pulse generator (Doric Lenses, Canada) 
and coupled to an optical fibre of 200 µm diameter and 0.39 NA (Thorlabs) via an adjustable collimator (CNI). 
Implanted optic fibres were connected via zirconia sleeves (Thorlabs) to an optic fibre cable attached via a com-
mutator (Doric Lenses, Canada). For all optogenetic stimulations, 5 ms light pulses (power 2.0–5 mW, wave-
length 532 nm) were delivered unilaterally at a frequency of 20 Hz for episodes of 5 s, alternating with 5 s pauses. 
Stimulation was given for either 1 min (Y-maze, ITI-phase), 2 min (Y-maze, test-phase), 3 min (all stimulations 
in the open field, Y-maze ITI + test-phase stimulation, elevated plus-maze) or 5 min (all remaining behavioural 
tests). Stimulation-sequences were delivered once per day, with a minimum 2 day recovery time for each hemi-
sphere before subsequent stimulations. This was necessary as repeated stimulations with shorter intervals could 
increase the risk of inducing seizures in some animals. Animals experiencing optogenetically-induced seizures 
were not used in subsequent experiments and data from the experiment in which a seizure was observed were not 
included in any analyses. Optical power at the ferrule connected to the implanted optic fibre was measured before 
and after testing of each animal. Data for individual tests were excluded for Chronos-transfected animals if the 
power measured at the end of testing was more than 0.5 mW lower than the level determined during calibration 
(next section).
Optogenetically-induced hyperlocomotion. Mice of both groups were first optogenetically stimulated unilaterally 
for 3 min, starting at minute 15 of a 30 min exploration of an open field (l 43 cm, w 22 cm, h 20 cm; San Diego 
Instruments), and the number of infrared beam breaks was used as a locomotor activity readout. Starting at 
2 mW, optical power was increased in 0.5 mW increments, and locomotor activity during optogenetic stimulation 
was measured; different hemispheres were tested on consecutive days. Calibration was terminated when hyper-
locomotion of >115% of baseline (an average of the preceding 9 min baseline period) was observed twice at the 
same stimulation power in the same hemisphere in Chronos animals. The optimal power to be used in all sub-
sequent experiments was determined for each animal individually from this calibration (LH: n = 7, RH: n = 11). 
GFP-transfected animals (controls) experienced a similar “calibration” alongside Chronos-transfected animals, 
to ensure comparable prior experience and control for non-specific effects of illumination. Power levels and the 
hemisphere receiving stimulation in control animals were matched to the Chronos group where possible. In cases 
where there were more GFP than Chronos animals, the power for the additional animals was set to intermediate 
values to ensure the same mean power in both groups. Unilateral stimulation, and the calibration of optical power 
for each animal was necessary to exclude animals displaying optogenetically-induced seizures, which we found 
were likely due to strong offsite expression in the dentate gyrus and/or CA3. To experimentally test the effects 
of optogenetic stimulation on locomotor activity, this procedure was repeated in a novel open field (40 × 40 cm, 
25 cm wall height). Distance moved was measured in 3-minute bins via video-tracking (AnyMaze, San Diego 
Instruments, CA, USA). On a later occasion, the experiment was repeated twice in that same open field 1 h after 
injection of either 1 mg/kg of the D2-receptor antagonist raclopride (10 µl/g, i.p; Sigma-Aldrich, UK) or vehicle 
(saline; within-subject design). The order of drug exposure (raclopride/vehicle) was counterbalanced and there 
were three days between each test.
Effects of optogenetic stimulation on spatial novelty preference (SNP). We assessed hippocampus-dependent 
short-term memory using the SNP Y-Maze task45. This task involves familiarizing animals with part of an 
environment, and then allowing exploration of both the familiar part of the environment and a novel area (see 
Fig. 2a). Due to rodents’ innate preference to explore novel spaces, animals should preferentially explore the 
novel area during the test phase45,65. For the SNP-test with optogenetic stimulation, mice were tethered to the 
optical fibre and left to acclimatize to a novel holding cage for 5 min before testing. They were then transferred 
to a transparent Y-shaped maze, filled with sawdust for 5 min, in which 1 of the 2 goal arms was blocked (sample 
phase). After a 1 min intra-trial interval (ITI) in the holding cage, mice were returned to the Y-maze for a 2 min 
test phase, in which both goal arms were accessible. Distance moved and time spent in each arm was measured via 
video-tracking (AnyMaze, San Diego Instruments, CA, USA). Mice were tested 4 times, in the same apparatus, 
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but located in different rooms, and stimulation was applied during different stages of the task; either during (1) 
the sample phase (2) the ITI, (3) the test, or (4) throughout both the ITI and test phases (see Fig. 2a). To avoid the 
risk of overstimulation, sample-phase stimulation (5 min) was run last for all animals, and we did not stimulate 
throughout both the sample and test phases in the same trial. Locomotor data represent distance travelled in all 
available portions of the maze (i.e. all 3 arms in the test phase, familiar and start arm in the sample phase), unless 
stated otherwise.
Effects of amphetamine on SNP and locomotion. For pharmacological experiments, the same protocol was fol-
lowed except that mice were injected with either amphetamine or saline-vehicle 30 min before testing (2.5 mg/kg, 
i.p; between-subject design) and placed in their home cage until 10 min before the sample phase when they 
were transferred to a novel holding cage (as above, Fig. 4a). A separate cohort of male wildtype mice was used 
(C57BL/6 J, Charles Rivers; n = 12 amphetamine treated, n = 11 vehicle).
Effects of optogenetic stimulation on anxiety in the elevated plus maze (EPM). Animals were tested on an EPM 
(72 cm above ground) with two opposite grey closed arms (w 7 cm, l 38 cm, h 21 cm), and two open white arms (w 
7 cm, l 38 cm). After tethering, mice had a 5 min acclimation period in a novel cage and optogenetic stimulation 
began in the last 20–30 s of this phase (see Fig. 3a). Mice were then placed in the centre of the EPM facing an open 
arm, and left to explore for 5 min, with optogenetic stimulation continuing for the first 2.5 min of testing (total 
stimulation time = 3 min). Distance moved was measured via video tracking (AnyMaze, San Diego Instruments, 
CA, USA), and time spent in each arm was scored manually offline, blind to experimental group. Data presented 
are from the first 2.5 min of the test (during optogenetic stimulation).
Effects of optogenetic stimulation on place preference (PP). To test whether stimulation during the Y-Maze task 
was sufficient to induce a PP within the time-scale of minutes, we adapted the Y-Maze test to resemble a condi-
tioned PP paradigm (see Fig. 3d). The start arm was blocked throughout, leaving accessible a V-shaped maze with 
two goal arms and a centre zone with removable doors for each arm. Animals were tethered throughout testing 
and were always introduced into the maze centre-zone with both doors closed. Animals went through two sample 
phases of 5 min, separated by a short ITI of 30–60 s, and received 5 min optogenetic stimulation during the second 
sample phase. In each sample phase only one arm was accessible (e.g. the left arm in the first phase and the right 
arm in the second phase, or vice versa). Animals were then placed in a holding cage for a 1 min ITI before being 
placed back into the maze. Both doors were removed, and mice were allowed to explore the entire maze for 2 min 
(test phase). Counterbalancing the order of stimulation was not possible given that the effects of stimulation on 
locomotion were found to last beyond the stimulation period in previous tests (see Fig. 1b,c), and might therefore 
carry-over to the time in the ‘non-stimulated’ arm given the short delays used here.
Animals were tested in a long-term PP task conducted in a modified 3–chamber apparatus (two 22 cm × 30 cm 
chambers joined by a 10 cm × 20 cm alley) over 3 days (see Fig. 3g). On day 1, animals were tethered (but not 
stimulated), placed in the central alley, and the sliding doors to both chambers were opened allowing exploration 
of the whole apparatus for 10 min. On day 2, animals began in the central alley and the door to one of the side 
compartments (left or right, counterbalanced) was opened. Once the animal entered the compartment the door 
was closed and the animal was left to explore for 5 min. For half the animals this first sample phase was paired 
with optogenetic stimulation. After a 2 h delay, animals were given a second sample phase (5 min) in the opposite 
chamber. Optogenetic stimulation was applied during the second sample phase for animals that did not receive it 
during the first sample. The following day, animals were placed in the central alley and both doors were opened to 
allow exploration of both chambers for 10 min. Animals were tethered for all phases of testing. Distance moved 
and time spent in each compartment were measured via video tracking (AnyMaze, San Diego Instruments, CA, 
USA). Only data for the first 5 min of the test phase are presented here.
Histology. Animals were euthanized with sodium pentobarbital (Euthatal) and perfused transcardially with 
PBS followed by 4% paraformaldehyde (PFA). Head caps with optic fibres were detached carefully and the brains 
were removed and fixed in PFA and then transferred to phosphate buffered saline (PBS). Coronal slices (60 μm) 
were cut on a vibratome (Leica), washed in PBS, then PBS containing 4′,6-diamidino-2-phenylindole (DAPI, 
1:1,000,000, Sigma) for 10 minutes. Slices were washed with PBS before mounting with Vectashield (Vector 
Labs, USA). Slices were scanned with a fluorescence microscope (Axio Zoom, Carl Zeiss) to detect DAPI and 
Chronos-GFP fluorescence.
Analysis. Data were tested for normality using the Shapiro-Wilks Test. Where data for both groups was nor-
mally distributed, parametric tests (t-test or ANOVA) were applied, otherwise non-parametric equivalents were 
used. A 3-way repeated-measures ANOVA was used for the raclopride experiment despite data for some condi-
tions not being normally distributed; however pairwise comparisons using appropriate non-parametric tests (not 
presented) yielded the same pattern of statistical significance. For t-test analyses, the adjusted t-values and df ’s are 
reported for instances where Levene’s test for equality of variances indicated significant differences. In all cases, 
parametric and non-parametric tests yielded similar results.
Data availability. All data generated or analysed during this study are included in this article. All numeric 
source data for the presented figures are available from the corresponding author on reasonable request at the 
desired level of analysis.
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